Ozonized sunflower oil, Oleozon, has a remarkable gerrmicidal action. In the present study, the efficacy of Oleozon in the treatment of tinea pedis was demonstrated in a controlled randomized phase III assay, comparing topical Oleozon with ketoconazole cream 2% (Nizoral) in 200 patients (100 in each group). The treatment administered was twice per day for a period of 6 weeks. The efficacy was evaluated clinically (disappearance of all lesions, with or without negative mycological results) and mycologically (negative culture results). A complete clinical and mycological cure was obtained in 75 and 81% for Oleozon and ketoconazole, respectively, with no significant differences between both groups. No side-effects or bacterial super-infections were observed. Patients were evaluated 6 months after the end of the treatment and no recurrence was observed in the Oleozon group. Oleozon can be an effective alternative low-cost antimycotic drug.

Mazorra (2014) Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab, mAbs, 6:3, 782-792,

The results of the use of ozonised sunflower oil (OLEOZON(®)) in the treatment of onychomycosis, based on its known antimycotic action and good skin tolerance, by means of a controlled randomised phase III assay are presented. A total of 400 outpatients were randomly divided into two groups: experimental, treated with topical OLEOZON(®), two times per day and control, treated also two times per day, with ketoconazole cream 2%, for 3 months. A patient was considered cured when the sick nails regained the normal colour, growth and thickness, with a negative mycological study. In the experimental group, a regression of signs was achieved from the first month of treatment, while in the control group, it was obtained after the third month of treatment. All patients treated with OLEOZON(®) had improvement in their condition (9.5%) or were cured (90.5%). However, in the control group, only 13.5% of patients were cured, 27.5% improved and 59% remained the same, with significant differences between both the groups. After 1 year of follow-up, experimental and control groups presented 2.8% and 44.4% of relapses, respectively. Topical OLEOZON(®) demonstrated effectiveness in the treatment of onychomycosis, superior to that of ketoconazole. No side effects were observed.

No abstract

No abstract